Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Authors
Meyer, TQian, W
Caplin, M
Armstrong, G
Lao-Sirieix, S
Hardy, R
Valle, Juan W
Talbot, D
Cunningham, D
Reed, N
Shaw, A
Navalkissoor, S
Luong, T
Corrie, P
Issue Date
2014-03
Metadata
Show full item recordAbstract
Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an acceptable regimen with or without adding cisplatin.Citation
Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. 2014, 50 (5):902-11 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2013.12.011PubMed ID
24445147Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2013.12.011
Scopus Count
Collections
Related articles
- Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
- Authors: Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M
- Issue date: 2014 Dec
- A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
- Authors: Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T
- Issue date: 2013 Sep 10
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
- Authors: Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T
- Issue date: 2010 Mar 30
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
- Authors: Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M, Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators.
- Issue date: 2013 May
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
- Authors: Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T
- Issue date: 2013 Apr